Immune Thrombocytopenia
Conditions
Keywords
Huaiqihuang granule, immune thrombocytopenia, randomized, double-blind, placebo-controlled,
Brief summary
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (Qi Yin deficiency).
Detailed description
The randomized clinical trial included subjects (n =216) will be randomly divided into experimental (n = 162) and control groups (n =54) according to a random number table. Patients in the experimental group will receive Huaiqihuang Granule . Patients in the control group will receive placebo a placebo-controlled designed is used for this study. To minimize the risks, treatment stopping rules and subsequent measures are established for subjects whose disease under study become worsening during the study. Subjects receiving placebo treatment will switch to investigational drug after Week 24 to reduce the risk of lack of efficacy by placebo. The primary outcome measures is proportion of patients whose hemorrhage has improved (clinical effective rate).
Interventions
DRUGPlacebo
Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Sponsors
Huazhong University of Science and Technology
Qidong Gaitianli Medicines Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
1 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged between 1 and 14 years (inclusive) ; 2. Is diagnosed as immune thrombocytopenia according to the criteria of ICD-10, i.e., platelet \< 100×109/L for at least two hematology tests with normal blood cell morphology; skin petechia, ecchymosis and (or) the clinical manifestations of mucosa and visceral hemorrhage; no splenomegaly; exclusion of other secondary thrombocytopenia, such as aplastic leukemia, aplastic anemia characterized by thrombocytopenia as the first hematologic abnormality, hereditary thrombocytopenia, thrombocytopenia secondary to other autoimmune diseases, infections or drugs etc... 3. Meet the diagnosis criteria for Qi Yin deficiency in traditional Chinese medicine; 4. Time since initial diagnosis of ITP until randomization is at least 12 month, i.e., course of disease ≥1 year; 5. Values of prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) are within 1.2 times of normal reference range; 6. Values of biochemistry parameters including creatinine, ALT, AST, glucose, total bilirubin are less than 1.2 time of the corresponding upper limit of normal range; 7. Has signed and dated the informed consent in volunteer by the subject and the subject's legal guardian(s) (for subject who is less than 8 years old, the informed consent will be signed and dated by the subject's legal guardian(s) in volunteer).
Exclusion criteria
1. Is diagnosed as congenital thrombocytopenia; 2. Is diagnosed as secondary thrombocytopenia; 3. Is diagnosed as non-immune thrombocytopenia; 4. Has medical history of diabetes; 5. In the judgement of Investigator, the subject is not appropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the proportion of subjects whose hemorrhage has improved (clinical effective rate) | 24、48 and 60 Weeks after treatment | The improvement of hemorrhage is defined if at least one of the following criteria is met: 1. Severity of hemorrhage decreases one or more grade, the severity of hemorrhage is defined as following: none: there is any hemorrhage manifestation; mild: simple (often related with an unnoticeable minor collision without obvious ecchymosis) or obvious ecchymosis by collision; moderate: mucous membrane hemorrhage (nose hemorrhage, gum, oral mucosa) and menorrhagia; and severe: organ hemorrhage (digestive tract, respiratory tract, intracranial, etc.). 2. Significant increase in platelet count defined as platelet count is over 30×109/L and increases more than twice compared with the baseline. The results must be tested at least twice with at least 7 days apart). 3. The score of quality of life improves one or more points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the recovery rate of immune function | 24、48 and 60 Weeks after treatment | The recovery rate of immune function is the proportion of subjects who have normalized immune function after treatment. The parameters of immune function include cytokines, lymphocyte subsets and auto immunity. One of the three tests has been restored to normal is defined as the immune function has returned to normal. |
| the recovery rate of thyroid function | 12、24、36、48、60 and 72 Weeks after treatment | The recovery rate of thyroid function is the proportion of subjects who have normalized immune function after treatment. |
Countries
China
Outcome results
None listed